Biomarkeri seruma u oralnom lišaju: biohemijska perspektiva

Serum Biomarkers and Disease Severity in Oral Lichen Planus

  • Jiawei Zhang Department of Geratology and Special Hospital Ward, Affiliated Hospital of Hebei University
  • Jie Yang Department of Infectious Diseases, Affiliated Hospital of Hebei University
  • Wei Lu Department of Laboratory Pathology, The 82nd Group Military Hospital of the Chinese People's Liberation Army
  • Shasha Zang Department of Geratology and Special Hospital Ward, Affiliated Hospital of Hebei University
  • Chengbi Tong Department of Laboratory, Affiliated Hospital of Hebei University
DOI: https://doi.org/10.5937/jomb0-57322

Sažetak


Background: Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal tissues of the oral cavity. Its pathogenesis involves immune dysregulation, angiogenesis, and psychological stress. Identifying reliable biomarkers can enhance diagnosis, monitor disease progression, and guide personalized treatment strategies. This study aimed to investigate five key serum biomarkers in OLP patients, including angiopoietin-2 (Ang-2), vitamin D, IgA, IgG, and cortisol, to explore their associations with disease severity.

Methods: This observational, case-control study enrolled 100 OLP patients and 80 healthy controls. The OLP patients were classified into three subtypes: reticular (n = 30), atrophic (n = 35), and erosive (n = 35). Fasting blood samples were collected, and serum levels of Ang-2, vitamin D, IgA, IgG, and cortisol were measured using ELISA, HPLC, immunoturbidimetry, and chemiluminescent immunoassays. Statistical analyses, including t-tests, ANOVA, and Pearson correlation, were performed to assess biomarker levels and their correlations with disease severity.

Results: Ang-2, IgA, and IgG levels were significantly elevated in OLP patients, particularly in the erosive subtype (P < 0.001), with positive correlations between these markers and disease severity. Vitamin D and cortisol levels were significantly reduced in OLP patients compared to controls (P < 0.01) and showed negative correlations with disease severity. These findings indicate the role of vascular, immune, metabolic, and stress-related factors in OLP pathogenesis.

Conclusion: Ang-2, vitamin D, IgA, IgG, and cortisol are valuable biomarkers for assessing OLP severity and guiding personalized treatment. Monitoring these biomarkers can aid in diagnosing OLP, tracking disease progression, and optimizing therapeutic strategies.

Reference

1. Louisy A, Humbert E, Samimi M. Oral Lichen Planus: An Update on Diagnosis and Management. Am J Clin Dermatol 2024; 25(1): 35-53.
2. El-Howati A, Thornhill MH, Colley HE, Murdoch C. Immune mechanisms in oral lichen planus. Oral Dis 2023; 29(4): 1400-15.
3. Zundell MP, Kaminetsky J, Lebwohl M, Gottlieb AB. Successful Treatment of Lichen Planus With Oral Upadacitinib. J Drugs Dermatol 2023; 22(10): 1058-60.
4. Mathew S, Lobo C, Antony M. Oral lichen planus. Clev Clin J Med 2023; 90(12): 717-8.
5. Manchanda Y, Rathi SK, Joshi A, Das S. Oral Lichen Planus: An Updated Review of Etiopathogenesis, Clinical Presentation, and Management. Indian Dermatol Onl 2024; 15(1): 8-23.
6. Gonzalez-Moles MA, Ramos-Garcia P. Oral lichen planus and related lesions. What should we accept based on the available evidence? Oral Dis 2023; 29(7): 2624-37.
7. Qing M, Yang D, Shang Q, Peng J, Deng J, Lu J, et al. CD8(+) tissue-resident memory T cells induce oral lichen planus erosion via cytokine network. Elife 2023; 12(
8. De D, Jain S, Dev A, Chatterjee D. Oral lichen planus-like lesions in skin of color: a review. Int J Dermatol 2024; 63(11): 1503-12.
9. Pedraca ES, Da SE, de Lima TB, Rados PV, Visioli F. Systemic non-steroidal immunomodulators for oral lichen planus treatment-a scoping review. Clin Oral Invest 2023; 27(12): 7091-114.
10. Chen X, Zhang S, Wu X, Lei Y, Lei B, Zhao Z. Inflammatory cytokines and oral lichen planus: a Mendelian randomization study. Front Immunol 2024; 15(1332317.
11. Nukaly HY, Halawani IR, Alghamdi S, Alruwaili AG, Binhezaim A, Algahamdi R, et al. Oral Lichen Planus: A Narrative Review Navigating Etiologies, Clinical Manifestations, Diagnostics, and Therapeutic Approaches. J Clin Med 2024; 13(17):
12. Bessar H, Hammad NM, Ismail T, Teama MA, Youssef A. Serum angiopoietin-2 level as a novel potential biomarker in oral lichen planus. J Cosmet Dermatol-Us 2021; 20(9): 2940-4.
13. Saeed S, Choudhury P, Ahmad SA, Alam T, Panigrahi R, Aziz S, et al. Vitamin D in the Treatment of Oral Lichen Planus: A Systematic Review. Biomedicines 2022; 10(11):
14. Druzijanic A, Cigic L, Glavina A, Draganja M, Martinovic D, Kovic M. Serum Concentration of Vitamin D in Patients with Oral Lichen Planus. Acta Stomatol Croat 2023; 57(3): 265-72.
15. Ge X, Yuan L, Wei J, Nguyen T, Tang C, Liao W, et al. Vitamin D/VDR signaling induces miR-27a/b expression in oral lichen planus. Sci Rep-Uk 2020; 10(1): 301.
16. Mozaffari HR, Zavattaro E, Abdolahnejad A, Lopez-Jornet P, Omidpanah N, Sharifi R, et al. Serum and Salivary IgA, IgG, and IgM Levels in Oral Lichen Planus: A Systematic Review and Meta-Analysis of Case-Control Studies. Medicina-Lithuania 2018; 54(6):
17. Al-Zanqaly S, El-Barbary RA, Abdelaziz SY, Ali MS. Assessment of serum levels of anti-gliadin (IgA and IgG) antibodies in patients with lichen planus: A pilot study. Egypt J Immunol 2023; 30(4): 21-9.
18. Mao F, Dong Y, Wang Z, Cai L, Pan D, Zhang C, et al. Direct immunofluorescence and immune function in patients with oral lichen planus. J Dent Sci 2022; 17(2): 795-801.
19. Leroy C, Lesclous P, Dutot N, Anquetil M, Tessier MH. Erosive oral lichen planus: Think thymoma. Ann Dermatol Vener 2023; 150(2): 152-4.
20. Wu T, Bai Y, Jing Y, Chen F. What can we learn from treatments of oral lichen planus? Front Cell Infect Mi 2024; 14: 1279220.
21. Spirito F, Caponio V, Lo ME, Campisi G, Santarelli A, Lo RL, et al. Oral lichen planus in children: An Italian case series. Pediatr Dermatol 2023; 40(3): 489-93.
Objavljeno
2025/04/10
Broj časopisa
Vol. 44 Br. 6 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2025 Jiawei Zhang, Jie Yang, Wei Lu, Shasha Zang, Chengbi Tong

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.